Literature DB >> 28838145

Valganciclovir for the Suppression of Epstein-Barr Virus Replication.

Jessica E Yager1, Amalia S Magaret2,3, Steven R Kuntz3, Stacy Selke3, Meei-Li Huang3, Lawrence Corey2,3,4, Corey Casper2,4,5, Anna Wald2,3,4,5.   

Abstract

Epstein-Barr virus (EBV) causes infectious mononucleosis and can lead to lymphoproliferative diseases. We evaluated the effects of valganciclovir on oral EBV shedding in a randomized, double-blind, placebo-controlled study. Twenty-six men received oral valganciclovir or daily placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative treatment. Valganciclovir reduced the proportion of days with EBV detected from 61.3% to 17.8% (relative risk, 0.28; 95% confidence interval [CI], .21-.41; P < .001), and quantity of virus detected by 0.77 logs (95% CI, .62-.91 logs; P < .001). Further investigations into the impact of valganciclovir on EBV-associated diseases are needed.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Epstein-Barr virus; infectious mononucleosis; posttransplant lymphoproliferative disorder; valganciclovir; viral shedding

Mesh：

Substances：

Year:  2017        PMID： 28838145      PMCID： PMC5854009          DOI： 10.1093/infdis/jix263

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.

Authors:  Ashok Cattamanchi; Misty Saracino; Stacy Selke; Meei-Li Huang; Amalia Magaret; Connie Celum; Lawrence Corey; Anna Wald; Corey Casper
Journal:  J Med Virol       Date:  2011-10       Impact factor: 2.327

3.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.

Authors:  I A Darenkov; M A Marcarelli; G P Basadonna; A L Friedman; K M Lorber; J G Howe; J Crouch; M J Bia; A S Kliger; M I Lorber
Journal:  Transplantation       Date:  1997-09-27       Impact factor: 4.939

4.  Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.

Authors:  D P Funch; A M Walker; G Schneider; N J Ziyadeh; M D Pescovitz
Journal:  Am J Transplant       Date:  2005-12       Impact factor: 8.086

5.  Acyclovir for treatment of infectious mononucleosis: a meta-analysis.

Authors:  D Torre; R Tambini
Journal:  Scand J Infect Dis       Date:  1999

6.  Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx.

Authors:  J C Niederman; G Miller; H A Pearson; J S Pagano; J M Dowaliby
Journal:  N Engl J Med       Date:  1976-06-17       Impact factor: 91.245

7.  Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

8.  Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Authors:  Andrew M Evens; Kevin A David; Irene Helenowski; Beverly Nelson; Dixon Kaufman; Sheetal M Kircher; Alla Gimelfarb; Elise Hattersley; Lauren A Mauro; Borko Jovanovic; Amy Chadburn; Patrick Stiff; Jane N Winter; Jayesh Mehta; Koen Van Besien; Stephanie Gregory; Leo I Gordon; Jamile M Shammo; Scott E Smith; Sonali M Smith
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

9.  Oral mucosal reactivation rates of herpesviruses among HIV-1 seropositive persons.

Authors:  Elizabeth Griffin; Elizabeth Krantz; Stacy Selke; Meei-Li Huang; Anna Wald
Journal:  J Med Virol       Date:  2008-07       Impact factor: 2.327

10.  Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection.

Authors:  Sara Gianella; Christy M Anderson; Susanna R Var; Michelli F Oliveira; Steven M Lada; Milenka V Vargas; Marta Massanella; Susan J Little; Douglas D Richman; Matthew C Strain; Josué Pérez-Santiago; Davey M Smith
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103
View more
  7 in total

1.  A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis.

Authors:  Timothy S Blackwell; Justin C Hewlett; Wendi R Mason; Susan Martin; James Del Greco; Guixiao Ding; Pingsheng Wu; Lisa H Lancaster; James E Loyd; Rosemarie B Dudenhofer; Margaret L Salisbury; Jonathan A Kropski
Journal:  Ann Am Thorac Soc       Date:  2021-08

Review 2.  A new therapy in Epstein-Barr virus-associated lymphoproliferative disease: a case report and a revision of the literature.

Authors:  Lingling Xu; Hongjun Ba; Hongrong Lin; Liangying Zhong; Suping Li; Wen Tang; Zhiyong Ke; Ziyin Ye
Journal:  Ital J Pediatr       Date:  2019-11-04       Impact factor: 2.638

3.  Clinical characteristics and effectiveness of antiviral agents in hospitalized children with infectious mononucleosis in China: A multicenter retrospective study.

Authors:  Huili Hu; Huiling Deng; Jing Bi; Yi Xu; Shuangjie Li; Yue Xie; Xinrong Sun; Dongmeng Wang; Xufang Li; Wenxian Ouyang; Bing Hu; Yufeng Zhang; He Tang; Chunxiao Fang; Hui Zhang; Lingyun Guo; Chen Wang; Tianyi Wang; Fengxia Yang; Tao Jiang; Zhengde Xie; Gang Liu
Journal:  Pediatr Investig       Date:  2021-09-22

Review 4.  40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?

Authors:  Anna Majewska; Beata Mlynarczyk-Bonikowska
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 5.  Neurology of Acute Viral Infections.

Authors:  Jonathan D Krett; J David Beckham; Kenneth L Tyler; Amanda L Piquet; Lakshmi Chauhan; Carla J Wallace; Daniel M Pastula; Ronak K Kapadia
Journal:  Neurohospitalist       Date:  2022-05-27

6.  Quantification of Torque Teno Virus and Epstein-Barr Virus Is of Limited Value for Predicting the Net State of Immunosuppression After Lung Transplantation.

Authors:  Rickard Nordén; Jesper Magnusson; Anna Lundin; Ka-Wei Tang; Staffan Nilsson; Magnus Lindh; Lars-Magnus Andersson; Gerdt C Riise; Johan Westin
Journal:  Open Forum Infect Dis       Date:  2018-03-06       Impact factor: 3.835

7.  Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads.

Authors:  Catherine M Byrne; Christine Johnston; Jackson Orem; Fred Okuku; Meei-Li Huang; Habibur Rahman; Anna Wald; Lawrence Corey; Joshua T Schiffer; Corey Casper; Daniel Coombs; Soren Gantt
Journal:  PLoS Comput Biol       Date:  2021-06-21       Impact factor: 4.475
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.